Xilio Therapeutics, Inc. (XLO)
Develops cancer drugs that activate the immune system only inside tumors.
$9.15+0.01%Healthcare
StockGlow Score
Leaning Bullish
BearishBullish
1 year ago+0.5%
The outlook
XLO is trading above both its 50- and 200-day moving averages, sitting in the lower-middle portion of its 52-week range. Analyst targets average roughly double the current price, though coverage appears concentrated. Overall sentiment leans bullish based on current technical positioning.
What’s behind the score
Price trendAbove its 50- & 200-day averages
52-week range43% of the way from its 52-week low to high
Price targetAvg target +119% vs current price
Market cap
$60.2M
52-wk high
$12.74
52-wk low
$6.47
50-day avg
$8.65
200-day avg
$8.97
Trailing P/E
—